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I suggest another diagnosis for this child; I believe it may be a
case of hepatoerythropoietic porphyria (HEP). Hepatoerythro-
poietic porphyria (HEP) is a very rare type of autosomal recessive
porphyria caused by severe deﬁciency of uroporphyrinogen decar-
boxylase (UROD) [1]. Clinically it resembles congenital erythropoi-
etic porphyria (CEP), but biochemical ﬁndings are similar to those
found in porphyria cutanea tarda (PCT).
Deﬁciency in UROD activity was ﬁrstly described by Elder et al.
[3] in 1981. In most cases, the catalytic activity of UROD is below
10% of normal level. HEP is caused by biallelic (i.e., homozygous or
compound heterozygous) UROD mutations [2]. Several mutations
were identiﬁed in UROD gene of patients with HEP, indicating the
molecular heterogeneity of this disease [4e9]. Five to tenmutations
identiﬁed in HEPwere also found in family PCT (type II), which con-
ﬁrms the idea that HEP is the homozygous form of PCT [10]. Muta-
tions of UROD found in PCT apparently are more critical to the
enzymatic activity of UROD than the mutations found in HEP [11].
Clinical manifestations begin in childhood and are characterized
by severe photosensitivity, pruritus and bullous lesions that prog-
ress to mutilating scars on sun-exposed areas. These patients
have shortened distal phalanges, thickened skin, and severe hyper-
trichosis [12] (which worsens with age). Photosensitivity tends to
decrease with age. The sclerodermiform skin changes are similar
to those found in CEP. Erythrodontia and eye disorders can occur
in these patients. Some patients may develop hemolytic anemia
and hepatesplenomegalia [13,14].
Biochemical ﬁndings show increase in urinary porphyrins, pre-
dominantly URO and to a lesser extent heptacarboxyl porphyrin.
The ISOCOPRO has a concentration greater than or equal to COPRO
and can be found in urine and feces. Zn-PROTO in erythrocytes is
also increased. The increase in ISOCOPRO (urine and feces) and
Zn-PROTO (erythrocytes) are diagnostic criteria [14]. Some patients
may experience changes in liver enzymes, but serum iron levels are
normal. The pattern of urinary porphyrins in HEP is similar to that
found in PCT with a ratio URO/COPRO greater than 5: 1 and again it
is the increase in erythrocyte Zn-PROTO that allows the differenti-
ation [13].
Unlike PCT, as iron concentrations are normal, phlebotomy is not
effective in this disease. We treat our patients in Brazil with lowDOI of original article: http://dx.doi.org/10.1016/j.phoj.2016.04.001.
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and the photosensitivity and blisters improve. As the child grows
the number of blisters tend to decrease. Avoidance of sun exposure
is very important.References
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